ERIS vs MANKIND: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. ERIS LIFESCIENCES shows a lower P/E, a higher dividend yield and a higher net margin, while MANKIND PHARMA shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ERIS leads 8; MANKIND leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ERIS | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ERIS | MANKIND |
|---|---|---|
| Live Price | ₹1,355.5 | ₹2,280 |
| Day Change | -0.08% | 1.86% |
| Volume | 24,968 | 5.31 L |
| 52-Week High | ₹1,740 | ₹2,674 |
| 52-Week Low | ₹1,200 | ₹1,909.7 |
| Distance from 52W High | -22.1% | -14.73% |
Valuation
| Metric | ERIS | MANKIND |
|---|---|---|
| Market Cap | ₹18,777 Cr | ₹94,039 Cr |
| P/E Ratio | 28.98x | 45.89x |
| P/B Ratio | 4.81x | 5.77x |
| EPS | ₹10.28 | ₹13.9 |
| Book Value | ₹281.12 | ₹401 |
| Dividend Yield | 0.53% | 0% |
Growth
| Metric | ERIS | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 7.1% | 11.8% |
| EPS Growth (TTM YoY) | 200% | 31.7% |
| Qtr Sales Growth | 96.68% | 35.98% |
| Qtr Profit Growth | 196.73% | 2.79% |
Profitability & Leverage
| Metric | ERIS | MANKIND |
|---|---|---|
| ROE | 7.64% | 12.41% |
| ROCE | 6.96% | 11.87% |
| Net Margin | 19.89% | 13.34% |
| Operating Margin | 29.73% | 27.68% |
| Debt to Equity | 0.65x | 0.34x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ERIS | MANKIND |
|---|---|---|
| Promoter Holding | 54.14%▲ 0.22 pp | 72.63%▼ 0.03 pp |
| FII Holding | 5.75%▼ 0.64 pp | 9.45%▼ 0.79 pp |
| DII Holding | 20.72%▲ 0.37 pp | 15.39%▲ 0.93 pp |
| Public Holding | 19.4%▲ 0.07 pp | 2.53%▼ 0.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.